Skip Ribbon Commands
Skip to main content

Dr Han Shuting

Dr Han Shuting

BA (Hons), MBBChir, MRCP (S’pore), MMed (In. Med)

Associate Consultant

National Cancer Centre Singapore

Specialty: Medical Oncology

Sub-specialties: Medical Oncology

Clinical Appointments

  • Associate Consultant Division of Medical Oncology National Cancer Centre SingaporeNational Cancer Centre Singapore


Dr. Han Shuting is an Associate Consultant at the Department of Medical Oncology in National Cancer Centre Singapore. She graduated with Bachelor of Arts (Honours) from Christ’s College, Cambridge in 2010 and Bachelor of Medicine and Surgery (MBBChir) from Cambridge School of Clinical Medicine in 2013. Subsequently, she obtained her MRCP (UK) and MMed (Int. Med) accreditation in 2015. She completed her medical oncology training in National Cancer Centre (Singapore) in 2019.


MA (Hons) 2019 – University of Cambridge
MMed (Int. Med) 2015 – National University of Singapore

MRCP (Singapore) 2015 – Royal College of Physicians

MBBChir 2013 – University of Cambridge

BA (Hons) 2010 – University of Cambridge


Professional Appointments and Committee Memberships


Research Interests


1. Tailoring precision immunotherapy: coming to a clinic soon? ESMO Open 2020 Feb;5:e000631.

Shuting Han, Wai Ho Shuen, Who-Whong Wang, Esdy Nazim, Han Chong Toh

2. Defining precision cellular immunotherapy – seeking biomarkers to predict and optimize outcomes of T cell therapies in cancer. Precision Cancer Medicine 2019 Aug;2
Shuting Han, Who-Whong Wang, Esdy Rozali, Han Chong Toh

3. The empowerment of all modalities against cancer. Singapore Med J 2018 Nov;58(11): 560-1.

Shuting Han, Han Chong Toh.

4. Somatostatin receptor imaging in nasopharyngeal cancer. Annals of Nasopharynx Cancer 2018 Jan;2. 2-2.
Wenlong Nei, Amit Jain, Fu-Qiang Wang, Kin Khor Lih, Joe Yeong, Shuting Han, Kiattisa Sommat, Mei-Kim Ang, Soong Yoke Lim, Kelvin Loke

5. Risk of hepatitis B reactivation and the role of novel agents and stem-cell transplantation in multiple myeloma patients with hepatitis B virus (HBV) infection. Ann Oncol. 2012 Feb;23(2):421-6.
Mya DH, Han ST, Linn YC, Hwang WY, Goh YT, Tan DC.


Research Trials